Glycotope GmbH Report issue

For profit Phase 1 Phase 2
Founded: Heidelberg Germany (2001)
Status: Acquired by Octapharma (2015)

Organization Overview

First Clinical Trial
2009
NCT01222624
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Glycotope Biotechnology GmbH | Glycotope GmbH

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Infertility (Phase 2)

Infertility, Female (Phase 1)

Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 8